Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

August 21, 2023

Learn more about the latest Signatera™ data in high-risk breast cancer:

Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring during neoadjuvant therapy Updates from recent conferences highlighting how ctDNA-based MRD testing may inform adjuvant treatment decisions Patient case studies demonstrating the utility of Signatera™ testing across the breast cancer treatment continuum

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Pr

Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma

Understanding the BESPOKE CRC Study: Your Path to Confident Cancer Monitoring

ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Signatera Bladder Cancer Brochure

Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid

Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma

Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer

Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma

A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari

Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s

Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1

Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi

Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j

Genomic alterations in early-onset versus average-onset stage IV colorectal cancer